Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[A specific marker of thrombolysis: DDE complex].

J Soria, C Soria, M Mirshahi

    Comptes Rendus De L'Academie Des Sciences. Serie III, Sciences De La Vie
    |January 1, 1987
    PubMed
    Summary

    Monitoring thrombolytic therapy requires specific fibrin degradation product (FbDP) determination. A new Elisa technique specifically detects FbDP complexes, even with fragment D present, improving patient monitoring.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Cognitive Functioning in Adults with Phenylketonuria in a Cohort of Spanish Patients.

    Behavioural neurology·2023
    Same author

    High impact of COVID-19 outbreak in a nursing home in the Nouvelle-Aquitaine region, France, March to April 2020.

    BMC infectious diseases·2021
    Same author

    Definition of minimal disease activity in psoriasis.

    Journal of the European Academy of Dermatology and Venereology : JEADV·2020
    Same author

    [Prevalence of osteoarticular infections by Enterobacteria producing extended-spectrum -lactamases].

    Acta ortopedica mexicana·2020
    Same author

    JUNO, the receptor of sperm IZUMO1, is expressed by the human oocyte and is essential for human fertilisation.

    Human reproduction (Oxford, England)·2018
    Same author

    Redefining the therapeutic objective in psoriatic patients candidates for biological therapy.

    The Journal of dermatological treatment·2017

    Area of Science:

    • Biochemistry
    • Immunology
    • Medical Diagnostics

    Context:

    • Thrombolytic therapy, often using tissue-type plasminogen activator (tPA), leads to fibrinogen degradation.
    • Fragment D, a fibrinogen degradation product, is present in patients undergoing thrombolytic therapy.
    • Accurate measurement of fibrin degradation products (FbDP) is crucial for monitoring treatment efficacy and safety.

    Purpose:

    • To develop a novel Enzyme-Linked Immunosorbent Assay (Elisa) technique for the specific determination of fibrin degradation products (FbDP).
    • To differentiate and quantify FbDP, particularly DDE complexes, in the presence of fragment D.
    • To provide a more accurate method for monitoring thrombolytic therapy.

    Summary:

    • A new Elisa technique immobilizes an anti-D neo monoclonal antibody to capture FbDP and fragment D from plasma.

    Related Experiment Videos

  • This antibody recognizes an accessible epitope on fragment D but not on undegraded fibrinogen.
  • DDE complexes are then specifically detected using a peroxidase-labelled anti-E antibody, enabling precise FbDP quantification.

    • Impact:

    • This method offers a significant advantage in accurately assessing thrombolytic therapy.
    • Improved monitoring can lead to better patient outcomes and treatment adjustments.
    • The technique enhances diagnostic specificity in complex biological samples.